|
Market Closed -
Nasdaq
23:00:00 07/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 24.77 USD | -1.82% |
|
+1.31% | -10.64% |
| 09-09 | Beam Therapeutics Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 01:00 PM | |
| 09-08 | Shares of Beam Therapeutics Retreat After Updated Trial Data Disappoints | DJ |
Company Valuation: Beam Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,327 | 2,692 | 2,159 | 1,974 | 2,736 | 2,475 | - | - |
| Change | - | -49.47% | -19.78% | -8.58% | 38.6% | -9.53% | - | - |
| Enterprise Value (EV) 1 | 4,367 | 1,613 | 969.4 | 1,974 | 2,441 | 1,559 | 1,254 | 1,629 |
| Change | - | -63.05% | -39.92% | 103.62% | 23.66% | -36.14% | -19.58% | 29.95% |
| P/E | -13.8x | -9.47x | -15.8x | -5.41x | -34.2x | -5.61x | -5.19x | -5.59x |
| PBR | 6.19x | 3.66x | 2.14x | 2.83x | 2.28x | 2.95x | 2.63x | 3.89x |
| PEG | - | 0.3x | 0.3x | -0x | 0.4x | -0x | -0.64x | 0.77x |
| Capitalization / Revenue | 103x | 44.2x | 5.72x | 31.1x | 19.6x | 51x | 39.4x | 20.1x |
| EV / Revenue | 84.2x | 26.5x | 2.57x | 31.1x | 17.5x | 32.1x | 20x | 13.2x |
| EV / EBITDA | -11.3x | -4.97x | -6.2x | -5.01x | -6.75x | -3.32x | -2.34x | -3.17x |
| EV / EBIT | -11.1x | -4.77x | -5.49x | -4.75x | -6.36x | -3.16x | -2.25x | -2.86x |
| EV / FCF | -38.6x | -61.1x | -5.3x | -5.54x | -6.78x | -10.3x | -6.93x | -8.79x |
| FCF Yield | -2.59% | -1.64% | -18.9% | -18% | -14.8% | -9.73% | -14.4% | -11.4% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -5.77 | -4.13 | -1.72 | -4.58 | -0.81 | -4.418 | -4.774 | -4.428 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 51.84 | 60.92 | 377.7 | 63.52 | 139.7 | 48.57 | 62.75 | 123.3 |
| EBITDA 1 | -385 | -324.3 | -156.5 | -393.6 | -361.4 | -470.2 | -536.4 | -513.8 |
| EBIT 1 | -392.5 | -338.5 | -176.5 | -415.6 | -383.7 | -493.7 | -557.8 | -569.9 |
| Net income 1 | -370.6 | -289.1 | -132.5 | -376.7 | -79.99 | -461.8 | -536.6 | -537.8 |
| Net Debt 1 | -960.4 | -1,078 | -1,190 | - | -294.9 | -916.4 | -1,222 | -846.2 |
| Reference price 2 | 79.69 | 39.11 | 27.22 | 24.80 | 27.72 | 24.77 | 24.77 | 24.77 |
| Nbr of stocks (in thousands) | 66,849 | 68,821 | 79,326 | 79,592 | 98,693 | 99,926 | - | - |
| Announcement Date | 2/28/22 A | 2/28/23 A | 2/27/24 A | 2/25/25 A | 2/24/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.61x | 32.09x | -3.32x | -.--% | 2.48B | |
| 21.73x | 7.76x | 15.59x | 1.37% | 74.68B | |
| 30.5x | 8.78x | 27.34x | 0.04% | 58.7B | |
| 33.66x | 6.05x | 18.11x | 0.96% | 48.36B | |
| -20.81x | 215.3x | -22.29x | -.--% | 43.05B | |
| 33.24x | 3.23x | 13.97x | -.--% | 42.48B | |
| 48.26x | 5.5x | 30.21x | -.--% | 41.39B | |
| 27.77x | 7.89x | 20.51x | 0.41% | 31.29B | |
| -14.93x | 5.54x | -6.96x | -.--% | 23.93B | |
| -61.76x | 11.97x | -60.92x | -.--% | 22.22B | |
| Average | 9.21x | 30.41x | 3.22x | 0.28% | 38.86B | |
| Weighted average by Cap. | 17.19x | 30.23x | 9.37x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BEAM Stock
- Valuation Beam Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
